TICKERNERD
Menu
ACOGACOGHealthcare · Biotechnology

ACOG Stock Forecast: Alpha Cognition, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$8.65
−1.70% on the day

The 6 Wall Street analysts covering Alpha Cognition, Inc. hold a median 12-month price target of $20 — +131.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 14 Oct 2026 — in the upper half.

Market cap
$188.4M
Ticker Nerd rank
55 / 100
Median analyst target
$20
Analysts covering
6
Revenue$6.1M+267.6% y/y
Operating income−$7.8M
Net income−$8.8M
Free cash flow−$12.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.3%
1M
−0.7%
YTD
+33.1%
1Y
+23.9%
From 52W high
−11.3%
From 52W low
+92.2%
$4.50
$9.75
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ACOG stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alpha Cognition, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
55 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
91
Size
68
Quality
62
Momentum
57
Value
54
Volatility
45
Growth
43
Issuance
29
Accruals
13

Revisions (91): Analysts have, on balance, been raising their forecasts.

Accruals (13): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ACOG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACOG, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26ACOGHigh $21Median $20Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $12Median $20High $21

The green dot is the last close — the median target sits +131.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Aug 2026B. Riley SecuritiesInitiatesBuy$21
17 Aug 2026HC Wainwright & Co.MaintainsBuy$18 → $20
10 July 2026Raymond JamesInitiatesOutperform—
29 May 2026Maxim GroupInitiatesBuy—
22 May 2026HC Wainwright & Co.ReiteratesBuy—
27 Apr 2026HC Wainwright & Co.ReiteratesBuy—
17 Apr 2026Craig-HallumInitiatesBuy—
19 Dec 2025HC Wainwright & Co.ReiteratesBuy—
20 Oct 2025HC Wainwright & Co.MaintainsBuy—
16 May 2025HC Wainwright & Co.ReiteratesBuy—
1 Apr 2025HC Wainwright & Co.ReiteratesBuy—
31 Mar 2025HC Wainwright & Co.ReiteratesBuy—
18 Mar 2025HC Wainwright & Co.InitiatesBuy$20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACOG appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ACOG vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Alpha Cognition, Inc. returned +23.9% against +17.5% for the S&P 500, dividends included.

ACOG vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Jan 26Apr 26Jul 26Oct 26ACOGS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ACOG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Alpha Cognition, Inc. (ACOG) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−7.4×

Cheaper than 92% of US stocks

Price / sales
12.3×

Cheaper than 12% of US stocks

Price / book
3.6×

Cheaper than 26% of US stocks

EV / EBITDA
−5.5×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
267.6%

Higher than 96% of US stocks

Earnings growth (YoY)
267.6%

Higher than 92% of US stocks

Gross margin
93.6%

Higher than 97% of US stocks

Operating margin
−127.3%

Higher than 13% of US stocks

Net margin
−137.7%

Higher than 4% of US stocks

Returns & dividend
Return on equity
−49.5%

Higher than 21% of US stocks

Return on assets
−30.4%

Higher than 14% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Alpha Cognition, Inc. (ACOG) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Alpha Cognition, Inc. has a market value of $188.4M and an enterprise value of $147.0M.

  • Revenue in the twelve months to 30 June 2026: $15.3M. The latest quarter grew 267.6% year on year.

  • Net income over the same four quarters: −$23.4M, a −153.6% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$37.1M.

  • Shares outstanding: 21.8M.

  • Trailing P/E: −7.4×; forward P/E: −14.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%.

  • Alpha Cognition, Inc. employs 71 people — $215K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Oct 2026

Data provided by Twelve Data

Peers

ACOG vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ACOGAlpha Cognition, Inc.$188.4M
55
CGENCompugen Ltd.$189.1M
86
UPBUpstream Bio, Inc.$187.3M
25
RNACCartesian Therapeutics, Inc.$185.8M
27
ELDNEledon Pharmaceuticals, Inc.$182.8M
33
SIONSionna Therapeutics, Inc.$182.5M
28
LYELLyell Immunopharma, Inc.$195.8M
64

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Alpha Cognition, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ACOG news & analysis

Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL®

Business Wire · 13 Oct 2026positive

Alpha Cognition announced that the USPTO published U.S. Patent Application No. 19/090,242, titled “Process for Preparing Benzgalantamine and Salts Thereof,” on October 1, 2026. The application relates to the company’s proprietary manufacturing process for ZUNVEYL®.

Why it matters — The publication concerns intellectual property associated with the manufacturing process for Alpha Cognition’s ZUNVEYL® product.

FAQ

Frequently asked questions about ACOG stock

What is the ACOG stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Alpha Cognition, Inc. have a median 12-month price target of $20, with estimates ranging from $12 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ACOG stock a buy right now?

Of the 6 analysts covering Alpha Cognition, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alpha Cognition, Inc. 55 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACOG?

As at 14 Oct 2026, Alpha Cognition, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (91 of 100).

Will ACOG stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +131.2% from the last close, and Ticker Nerd's factor model ranks Alpha Cognition, Inc. 55 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ACOG stock forecast for 2030?

No analyst covering Alpha Cognition, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACOG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $21 over the next 12 months.

How has ACOG stock performed over the past year?

Alpha Cognition, Inc. returned +23.9% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alpha Cognition, Inc. do?

Alpha Cognition Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for neurodegenerative diseases, with an emphasis on Alzheimer’s disease and cognitive impairment linked to mild traumatic brain injury.

What is the latest news on ACOG?

The most recent item we track (Business Wire, 13 Oct 2026): "Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL®". Alpha Cognition announced that the USPTO published U.S. Patent Application No. 19/090,242, titled “Process for Preparing Benzgalantamine and Salts Thereof,” on October 1, 2026. The application relates to the company’s proprietary manufacturing process for ZUNVEYL®.

Company

About Alpha Cognition, Inc.

Alpha Cognition Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for neurodegenerative diseases, with an emphasis on Alzheimer’s disease and cognitive impairment linked to mild traumatic brain injury. The company’s portfolio includes ZUNVEYL, an oral therapy marketed for mild-to-moderate Alzheimer’s disease, alongside additional programs in development that explore alternative formulations and combination approaches for broader dementia-related needs. Alpha Cognition also works on research programs targeting amyotrophic lateral sclerosis and other neurodegenerative conditions. Based in Vancouver, Canada, the company operates in the neuroscience and biotechnology markets, addressing areas where treatment options remain limited and clinical need is high.

CEO Mr. Michael E. McFadden B.B.A. · 71 employees · United States · https://www.alphacognition.com